학술논문
Persistence of Neutralizing Antibodies and Clinical Protection up to 12 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the Elderly.
Document Type
Article
Author
Collarino, Rocco; Vauloup-Fellous, Christelle; Allemang-Trivalle, Aude; Mouna, Lina; Baudouin, Edouard-Pierre; Keravec, Héloise; Neiss, Marie; Bouchareb, Souhila; Bessai, Cherif; Sanchez-Tamayo, Jorge; Pujol, Tom; Trikha, Zeynab; Brunetti, Nicoletta; Sitbon-Guichardon, Magali; Roque-Afonso, Anne Marie; Trivalle, Christophe
Source
Subject
*COVID-19
Language
ISSN
2328-8957
Abstract
Background Coronavirus disease 2019 (COVID-19) has severely affected the elderly, who are expected to display decreased immune responses due to immunosenescence. Methods This study retrospectively assesses neutralizing antibody (NAb) production up to 12 months after infection in long-term care patients. We used Roche Diagnostics immunoassay to quantify anti-spike (S) antibodies and a competitive immunoassay from YHLO as a surrogate test for NAb. Results We included 91 patients (mean age, 86 years). There was no significant variation in anti-S titers over time. There was a significant decrease of NAb titers between month 3 and month 6 but no further significant change up to month 12. Overall, 75 of 91 (82%) and 52 of 91 (57%) patients had, at least once, anti-S titers >75 U/mL and NAb titers >50 AU/mL, respectively, corresponding to a significant neutralizing activity in vitro. All 68 patients studied at M12 had detectable anti-S antibodies and 60 (88%) had detectable NAb; 60 of 68 (88%) and 29 of 68 (42.6%) still had anti-S titers >75 U/mL and NAb titers >50 AU/mL. Higher NAb titers were correlated with severe infection, higher levels of C-reactive protein, and lower lymphocyte counts. No patient developed reinfection. Conclusions Elderly people can display robust and persistent humoral response after severe acute respiratory syndrome coronavirus 2 infection, with NAb lasting up to 12 months. [ABSTRACT FROM AUTHOR]